ESTRO 2025 - Abstract Book

S1624

Clinical – äediatric tumours

ESTRO 2025

Figure 2.

Conclusion: In selected cases proton treatment can offer both lower doses to organs at risk and less low dose spread compared to photon treatment in children treated for neuroblastoma in the abdomen.

Keywords: Neuroblastoma, comparative treatment plans

1490

Mini-Oral Growth hormone deficiency in relation to radiation dose to the hypothalamus and pituitary gland in children treated with proton beam therapy Martin Bischoff 1,2 , Sabine Frisch 1 , Sarah Peters 1 , Dalia Ahmad Khalil 1 , Benjamin Koska 3 , Cordula Kiewert 4 , Stephan Tippelt 5 , Rolf-Dieter Kortmann 6 , Carsten Friedrich 7 , Stefan Rutkowski 8 , Beate Timmermann 1,9 1 Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Essen, Germany. 2 Department of Radiation Oncology, Ruhr-University Bochum, Medical Faculty, Marien Hospital, Herne, Germany. 3 University Hospital Essen, West German Proton Therapy Centre Essen (WPE), University Hospital Essen, West German Cancer Centre (WTZ), Essen, Germany. 4 Department of Pediatrics II, Division of Pediatric Endocrinology and Diabetology, University Hospital Essen, University of Duisburg Essen, Essen, Germany. 5 Department of Pediatrics III, Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany. 6 Department of Radiation Oncology, University of Leipzig, Leipzig, Germany. 7 Department of Pediatrics and Pediatric Hematology/Oncology, University Children’s Hospital, Carl von Ossietzky Universität Oldenburg, Klinikum Oldenburg AöR, Oldenburg, Germany. 8 Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 9 German Cancer Consortium (DKTK), German Essen/Düsseldorf, University Medicine Essen, Essen, Germany Purpose/Objective: Growth hormone deficiency (GHD) is a common finding in children who have received cranial radiotherapy (RT) while the dose to the hypothalamus and pituitary gland plays a crucial role [1]. We aimed to evaluate GHD in relation to the dose to hypothalamus/pituitary after proton beam therapy in paediatric patients with CNS or skull base tumours.